The shares of Natco Pharma climbed over 10 per cent intraday on May 24, 2021, following the Drug Controller General of India (DCGI) approval

The proposed Capex will increase the manufacturing capability of Quartz kitchen sink to 7,00,000 units per annum. The purpose of the expansion is to meet the increasing demand of Quartz kitchen sink in the international and the domestic market. A few of the notable marquee investors include Sunil Singhania (Abakkus Fund), Ashish Kacholia, and Varun Daga, who hold 6.45 per cent, 4.14 per cent, and 2.65 per cent, respectively in this stock.   

The consolidated net sales reported in Q1FY21 came in at Rs 430.87 crore, which declined by 5.62 per cent YoY from Rs 456.53 crore in Q1FY20. 

The consolidated net sales reported in Q1FY21 came in at Rs 852.41 crore, which declined by 64.07 per cent YoY from Rs 2,372.35 crore in Q1FY20.

The consolidated net sales reported in Q1FY21 came in at Rs 778.51 crore, which increased by 17.81 per cent YoY from Rs 660.81 crore in Q1FY20.

The consolidated net sales reported in Q1FY21 came in at Rs 2,910.83 crore, which increased by 2.29 per cent YoY from Rs 2,845.64 crore in Q1FY20. 

The consolidated net profit in Q1FY21 came in at Rs 29.69 crore, which rose by 40.11 per cent, as compared to Q1FY20, when it reported a profit of Rs 21.19 crore.

Standalone profit stood at Rs 6.5 crore for Q1FY21. It declined by 70.3 per cent as compared to Rs 21.9 crore that it had reported in Q1FY20.

The consolidated net sales reported in Q1FY21 came in at Rs 1,736.74 crore, which declined by 47.2 per cent YoY from Rs 3,289.47 crore in Q1FY20. 

The consolidated net profit in Q1FY21 came in at Rs 24.98 crore, which rose by 261.51 per cent, as compared to Q1FY20, when it reported a profit of Rs 6.91 crore.